+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton magnetic resonance spectroscopy of prefrontal lobe and thalamus in schizophrenics: correlation with clinical characteristics



Proton magnetic resonance spectroscopy of prefrontal lobe and thalamus in schizophrenics: correlation with clinical characteristics



Zhonghua Yi Xue Za Zhi 91(43): 3034-3039



To explore the characteristics of different subtypes of schizophrenics on prefrontal lobe and thalamus by proton magnetic resonance spectroscopy ((1)H-MRS) and its relationship. From August 2007 to April 2010 at our center, a total of 159 schizophrenics fulfilling the third edition criteria of Chinese Classification of Mental Disorders (CCMD-III) were recruited. And prefrontal lobe and thalamus were evaluated by multi-voxel (1)H-MRS. There were 88 males and 71 females. There were first-episode (n = 54) and not-first-episode (n = 105), negative subtype (n = 125) and positive subtype (n = 34), medicated (n = 96) and non-medicated (n = 63) by different criteria. The levels of N-acetylaspartate (NAA), choline-containing compounds (Cho) and creatine compounds (Cr) were measured and the ratios of NAA/Cr and Cho/Cr determined. Positive and negative syndrome scale (PANSS) and Wisconsin card sorting test (WCST) were also assessed. Only 45 normal controls received (1)H-MRS. On left prefrontal lobe and left thalamus, the NAA/Cr ratios in different subtypes of patients were lower than those in normal controls (P < 0.05 or 0.01). The NAA/Cr ratios in patients of non-first-episode (1.48 ± 0.34), negative subtype (1.40 ± 0.35) and medicated (1.47 ± 0.36) on right thalamus were also lower than those in normal controls (1.62 ± 0.37, t = 2.25, 3.56, 2.28, P < 0.05 or P < 0.01). Compared with positive subtype schizophrenics, the NAA/Cr ratios in those of negative subtype on right thalamus were lower (1.40 ± 0.35 vs 1.60 ± 0.37, t = 2.92, P < 0.01). On right thalamus of non-medicated schizophrenics, there was a negative correlation between the duration of illness and the ratio of NAA/Cr (r = -0.38, P < 0.05) and a positive correlation between the duration of illness and the ratio of Cho/Cr (r = 0.43, P < 0.01). On right thalamus of negative subtype schizophrenics, the ratios of NAA/Cr were negatively correlated with the total score of PANSS and the score of negative factor respectively (r = -0.36, -0.40, P < 0.05). On left prefrontal lobe of different subtypes, the ratios of NAA/Cr were negatively correlated with the total score of PANSS, the score of negative factor, responses errors and persistent errors (P < 0.01) and positively correlated with completed categories and conceptual level responses (P < 0.05 or P < 0.01). Abnormalities in neuronal function and/or integrity are present on left prefrontal lobe and left thalamus in schizophrenics. And right thalamus is probably involved in non-first-episode subtype, negative subtype and non-medicated subtype. Different subtypes of schizophrenics may have different characteristics of (1)H-MRS due to the duration of illness and their clinical symptoms.

(PDF emailed within 1 workday: $29.90)

Accession: 055260164

Download citation: RISBibTeXText

PMID: 22333054


Related references

Proton magnetic resonance spectroscopy study of prefrontal lobe and thalamus in schizophrenics on modified electroconvulsive therapy. Zhonghua Yi Xue Za Zhi 92(29): 2063-2065, 2013

The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). Pharmacopsychiatry 38(5): 214-219, 2005

Proton magnetic resonance spectroscopy of the frontal lobe in schizophrenics: a critical review of the methodology. Revista do Hospital das Clinicas 59(3): 145-152, 2004

Proton magnetic resonance spectroscopy (1H MRS) in schizophrenia: investigation of the right and left hippocampus, thalamus, and prefrontal cortex. Schizophrenia Bulletin 28(2): 329-339, 2003

Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. Schizophrenia Research 111(1-3): 86-93, 2009

Temporal lobe epilepsy: Correlation of proton magnetic resonance spectroscopy and 18F-fluorodeoxyglucose positron emission tomography. Magnetic Resonance in Medicine 37(1): 18-23, 1997

Metabolic change in the right dorsolateral prefrontal cortex and its correlation with symptom severity in patients with generalized anxiety disorder: Proton magnetic resonance spectroscopy at 3 Tesla. Psychiatry and Clinical Neurosciences 69(7): 422-430, 2016

31P-magnetic resonance spectroscopy in the dorsolateral prefrontal cortex of schizophrenics and depressed patients. Schizophrenia Research 18(2-3): 203, 1996

Proton magnetic resonance spectroscopy (1H-MRS) of the thalamus in schizophrenia. European Psychiatry 15(8): 489-491, 2001

31P magnetic resonance spectroscopy in the dorsolateral prefrontal cortex of schizophrenics and major depressed patients. Pharmacopsychiatry 28(5): 224, 1995

Proton magnetic resonance spectroscopy of the thalamus in patients with osteoarthritis of the hip. Bone and Joint Research 1(1): 8-12, 2012

Correlation between memory, proton magnetic resonance spectroscopy, and interictal epileptiform discharges in temporal lobe epilepsy related to mesial temporal sclerosis. Epilepsy and Behavior 16(3): 447-453, 2010

Proton magnetic resonance spectroscopy of the thalamus in fatal familial insomnia. Neurology 48(3 SUPPL 2): A296, 1997

Correlation of atrophy and metabolic changes in temporal lobe epilepsy by combined quantitative magnetic resonance imaging 15 t and magnetic resonance spectroscopy 4 t. Epilepsia 32(SUPPL 1): 8, 1991

31P magnetic resonance spectroscopy in the dorsolateral prefrontal cortex of schizophrenics with a volume selective technique--preliminary findings. Biological Psychiatry 41(6): 644-648, 1997